Breaking News, Financial News

Financial Report: Alkermes 1Q

Revenues up 24% in the quarter

Alkermes
 
1Q Revenues:
$161.2 million (+24%)

1Q Loss: $30.7 million (loss of $24.4 million in 1Q14)

Comments: Manufacturing and royalty revenues from the company’s long-acting atypical antipsychotic franchise, RISPERDAL CONSTA and INVEGA SUSTENNA/XEPLION were $46.9 million, down 5%. Manufacturing and royalty revenues from AMPYRA/FAMPYRA were $36.5 million, up 77%. Sales of VIVITROL were $31.1 million, up 82%. R&D expenses were up 35% to $70.3 million.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters